BIOTECHNOLOGY VALUE FUND L P 13D and 13G filings for Palvella Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-11-14 4:19 pm Purchase | 2025-09-30 | 13G | Palvella Therapeutics, Inc. PVLA | BIOTECHNOLOGY VALUE FUND L P | 1,181,194 9.990% | 13,077 (+1.12%) | Filing |
| 2024-12-17 5:42 pm Purchase | 2024-12-13 | 13G | Palvella Therapeutics, Inc. PVLA | BIOTECHNOLOGY VALUE FUND L P | 1,168,117 9.990% | 1,168,117 (New Position) | Filing |